Megakaryon

Tokyo, Japan· Est. 2011

Developing mass-produced, allogeneic iPSC-derived platelet transfusions to overcome donor dependency and supply shortages in hematology.

megakaryon.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Estimated funding: $2.8B

AI Company Overview

Developing mass-produced, allogeneic iPSC-derived platelet transfusions to overcome donor dependency and supply shortages in hematology.

HematologyRegenerative Medicine

Technology Platform

Proprietary platform for mass-producing functional human platelets from HLA-homozygous induced pluripotent stem cells (iPSCs) via directed differentiation of megakaryocytes.

Opportunities

Addressing the global, chronic shortage of donor platelets with a scalable, standardized, and potentially safer off-the-shelf product; leveraging Sysmex's global diagnostics and healthcare network for development and commercialization.

Risk Factors

Clinical risks include demonstrating safety (particularly from residual iPSCs) and non-inferior efficacy versus donor platelets; commercial risks involve achieving cost-effective manufacturing at scale for a price-sensitive transfusion market.

Competitive Landscape

Competitors include other groups developing in vitro platelet production (e.g., PlateletBio, Arteriocyte). Megakaryon differentiates through its foundational IP from leading Japanese institutions, its HLA-homozygous iPSC strategy for broad compatibility, and the industrial/commercial backing of Sysmex.

More companies in Japan →